vTv Therapeutics Inc. - (VTVT): Price and Financial Metrics


vTv Therapeutics Inc. - (VTVT): $0.72

-0.03 (-3.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VTVT POWR Grades


  • VTVT scores best on the Sentiment dimension, with a Sentiment rank ahead of 94.53% of US stocks.
  • The strongest trend for VTVT is in Growth, which has been heading up over the past 126 days.
  • VTVT's current lowest rank is in the Momentum metric (where it is better than 10.16% of US stocks).

VTVT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for VTVT is -0.48 -- better than merely 4.7% of US stocks.
  • VTVT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.15% of US stocks.
  • Revenue growth over the past 12 months for vTv Therapeutics Inc comes in at 47,150%, a number that bests 99.93% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to vTv Therapeutics Inc, a group of peers worth examining would be ETON, LPCN, PLXP, PRTA, and KROS.
  • Visit VTVT's SEC page to see the company's official filings. To visit the company's web site, go to www.vtvtherapeutics.com.

VTVT Valuation Summary

  • In comparison to the median Healthcare stock, VTVT's EV/EBIT ratio is 200.68% lower, now standing at -29.5.
  • Over the past 74 months, VTVT's EV/EBIT ratio has gone down 16.9.
  • Over the past 74 months, VTVT's price/sales ratio has gone down 218.2.

Below are key valuation metrics over time for VTVT.

Stock Date P/S P/B P/E EV/EBIT
VTVT 2021-08-31 21.0 -3.3 -29.6 -29.5
VTVT 2021-08-30 21.3 -3.3 -29.9 -29.8
VTVT 2021-08-27 20.8 -3.2 -29.3 -29.2
VTVT 2021-08-26 20.5 -3.2 -28.8 -28.6
VTVT 2021-08-25 20.8 -3.2 -29.3 -29.2
VTVT 2021-08-24 19.9 -3.1 -28.0 -27.8

VTVT Growth Metrics

    Its year over year cash and equivalents growth rate is now at 190.74%.
  • Its 5 year net income to common stockholders growth rate is now at 59.96%.
  • The 4 year cash and equivalents growth rate now stands at -96.15%.
Over the past 49 months, VTVT's revenue has gone up $10,299,000.

The table below shows VTVT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 10.395 -15.103 -4.81
2021-06-30 7.402 -16.943 -5.256
2021-03-31 7.393 -17.739 -8.016
2020-12-31 6.414 -18 -8.499
2020-09-30 0.022 -21.664 -14.658
2020-06-30 0.023 -22.425 -17.24

VTVT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VTVT has a Quality Grade of D, ranking ahead of 9.32% of graded US stocks.
  • VTVT's asset turnover comes in at 0.491 -- ranking 86th of 682 Pharmaceutical Products stocks.
  • TVTX, ASRT, and AMPH are the stocks whose asset turnover ratios are most correlated with VTVT.

The table below shows VTVT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.491 1 -1.393
2021-03-31 0.601 1 -5.046
2020-12-31 0.644 1 196.403
2020-09-30 0.003 1 20.944
2020-06-30 0.003 1 38.942
2020-03-31 0.212 1 -34.603

VTVT Price Target

For more insight on analysts targets of VTVT, see our VTVT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.75 Average Broker Recommendation 1.5 (Moderate Buy)

VTVT Stock Price Chart Interactive Chart >

Price chart for VTVT

VTVT Price/Volume Stats

Current price $0.72 52-week high $2.27
Prev. close $0.75 52-week low $0.38
Day low $0.72 Volume 48,700
Day high $0.76 Avg. volume 575,198
50-day MA $0.63 Dividend yield N/A
200-day MA $0.96 Market Cap 64.85M

vTv Therapeutics Inc. - (VTVT) Company Bio


vTv Therapeutics Inc., a biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company was founded in 2015 and is based in High Point, North Carolina.


VTVT Latest News Stream


Event/Time News Detail
Loading, please wait...

VTVT Latest Social Stream


Loading social stream, please wait...

View Full VTVT Social Stream

Latest VTVT News From Around the Web

Below are the latest news stories about vTv Therapeutics Inc that investors may wish to consider to help them evaluate VTVT as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning!

William White on InvestorPlace | February 18, 2022

H.C. Wainwright Thinks vTv Therapeutics’ Stock is Going to Recover

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on vTv Therapeutics (VTVT – Research Report) today and set a price target of $6.00. The company's shares closed last Wednesday at $0.84, close to its 52-week low of $0.83. According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.0% and a 35.3% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Eledon Pharmaceuticals, and Citius Pharmaceuticals. Currently, the analyst consensus on vTv Therapeutics is a Moderate Buy with an average price target of $6.00. See Insiders’ Hot Stocks on TipRanks >> vTv Therapeutics' market cap is currently $75.

Christine Brown on TipRanks | January 19, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

I hope you enjoyed the long weekend, but it's time to get back into investing with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | January 18, 2022

vTv Therapeutics Shares Updated Corporate Presentation

HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ: VTVT ), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population. Key Takeaways include: Hypoglycemia is common in people with type 1 diabetes and can occur quickly, with symptoms including sweating, nausea, coordination problems, headaches and even seizures. TTP399 may be used as a once-daily, oral adjunctive therapy in a $16B global insulin market for the reduction of hypoglycemic episodes. TTP399 has been test...

Benzinga | January 13, 2022

Winthrop Advisory Group LLC Buys Vanguard Extended Market Index ETF, Vanguard Intermediate-Term ...

Investment company Winthrop Advisory Group LLC (Current Portfolio) buys Vanguard Extended Market Index ETF, Vanguard Intermediate-Term Corporate Bond ETF, Vanguard Tax-Exempt Bond ETF, iShares Core U.S.

Yahoo | January 12, 2022

Read More 'VTVT' Stories Here

VTVT Price Returns

1-mo 0.22%
3-mo 9.09%
6-mo -28.00%
1-year -67.57%
3-year -49.30%
5-year -85.83%
YTD -27.64%
2021 -46.51%
2020 9.41%
2019 -35.85%
2018 -55.91%
2017 24.43%

Continue Researching VTVT

Want to see what other sources are saying about vTv Therapeutics Inc's financials and stock price? Try the links below:

vTv Therapeutics Inc (VTVT) Stock Price | Nasdaq
vTv Therapeutics Inc (VTVT) Stock Quote, History and News - Yahoo Finance
vTv Therapeutics Inc (VTVT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.665 seconds.